Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b Study of BG-C9074 in Advanced Solid Tumors
jRCT2031250755Phase 1Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of BG-C9074 in Nonhematologic neoplasms (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of participants with adverse events and serious adverse events, Maximum tolerated dose (MTD) of BG-C9074 and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
BG-C9074
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250755.